Law360, New York (May 13, 2009, 12:00 AM ET) -- The American Antitrust Institute has urged the Federal Trade Commission to scrutinize Express Scripts Inc.’s planned acquisition of Next RX LLC, claiming the pharmacy benefits managers' merger would have dire anti-competitive effects on a market already dominated by a handful of players.
The AAI has asked the FTC to request more information relating to the proposed merger and thoroughly investigate the competitive impact of the deal, which seeks to combine two of the nation’s four largest pharmacy benefit managers, intermediary companies that process and pay prescription...
AAI Calls For Hard Look At Benefits Cos.' Merger
To view the full article, take a free trial now.
